A conventional strategy for identification of disease genes is to use microarrays to compare the level of gene-specific mRNA expression between patient and control samples. Inter-individual ...

It is a biting winter’s evening in Cambridge and apparently we are making history. This is the first serious public ...

A team of Canadian researchers has found an existing US Food and Drug Administration-approved drug that could significantly ...

Singer, songwriter, and producer Tay Iwar, known for his unique fusion of R&B and Afro-fusion, is back with a new single, “Patience & Heart,” part of his two-track collection “In Your Absence.

Goldman Sachs has reiterated its 'sell' rating on Vodafone Idea following a weaker-than-expected second quarter, setting a target price of Rs 2.40, implying a 66% downside from Tuesday's BSE closing ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

New York-based The Goldman Sachs Group, Inc. (GS) is a financial institution that provides a range of financial services for corporations, financial institutions, governments, and high-net worth ...

This test identifies whether one or both parents carry genes for inherited disorders like cystic fibrosis, sickle cell anaemia, or Tay-Sachs disease. Why It’s Important: Understanding Genetic ...

“Fact Checking” with the Patient Community: An Industry-Advocacy Collaboration for Optimizing Trial Design: This poster is ...

On Monday night, Goldman Sachs chief US equity strategist David Kostin initiated a 2025 year-end S&P 500 target of 6,500, representing about an 11% gain in the benchmark index from current levels.

The S&P 500 Index will rise through the end of next year amid continued US economic expansion and earnings growth, according to Goldman Sachs Group Inc.’s chief equity strategist David Kostin.